🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

503 results for “Regeneron” Clear

  1. Placebo

    Regeneron UK Limited

    Heterozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  2. Placebo

    Regeneron UK Limited

    Atopic Dermatitis

    phase 3 small molecule completed

    3 trials

  3. Placebo

    Regeneron UK Limited

    Colorectal Neoplasms

    phase 3 small molecule completed

    1 trial

  4. Placebo

    Regeneron UK Limited

    Gout

    phase 3 small molecule completed

    1 trial

  5. Placebo (for alirocumab)

    Regeneron UK Limited

    Hypercholesterolemia

    phase 3 small molecule completed

    5 trials

  6. Pozelimab

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    4 trials

  7. Pozelimab

    Regeneron UK Limited

    CD55-deficient Protein-losing Enteropathy

    phase 3 small molecule completed

    1 trial

  8. Pozelimab

    Regeneron UK Limited

    Age-related Macular Degeneration (AMD)

    phase 3 small molecule active

    1 trial

  9. Pozelimab + Cemdisiran

    Regeneron UK Limited

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  10. Prompt aflibercept

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  11. Prompt aflibercept

    Regeneron UK Limited

    Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  12. REGN10933 + REGN10987

    Regeneron UK Limited

    Healthy Participants

    phase 3 small molecule completed

    1 trial

  13. REGN1908

    Regeneron UK Limited

    Allergic Conjunctivitis

    phase 3 small molecule completed

    1 trial

  14. REGN1908-1909

    Regeneron UK Limited

    Allergic Rhinitis Due to Cat Allergy

    phase 3 small molecule terminated

    1 trial

  15. REGN2810

    Regeneron UK Limited

    Non-small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  16. REGN2810/ipi

    Regeneron UK Limited

    Non-small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  17. REGN3918

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule terminated

    1 trial

  18. REGN475

    Regeneron UK Limited

    Osteoarthritis, Knee

    phase 3 small molecule completed

    1 trial

  19. REGN5713

    Regeneron UK Limited

    Allergic Conjunctivitis

    phase 3 small molecule active

    2 trials

  20. REGN5713

    Regeneron UK Limited

    Allergic Rhinitis

    phase 3 small molecule completed

    2 trials

  21. REGN7508

    Regeneron UK Limited

    Atrial Fibrillation (AF)

    phase 3 small molecule active

    2 trials

  22. REGN7508

    Regeneron UK Limited

    Cancer-Associated Thrombosis (CAT)

    phase 3 small molecule active

    1 trial

  23. REGN7508

    Regeneron UK Limited

    Peripheral Artery Disease (PAD)

    phase 3 small molecule active

    1 trial

  24. REGN7508

    Regeneron UK Limited

    Symptomatic Venous Thromboembolism (VTE)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources